Show simple item record

Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies

dc.contributor.authorSanchez-Piedra, C.
dc.contributor.authorDiaz-Torne, C.
dc.contributor.authorManero, J.
dc.contributor.authorPego Reigosa, José María 
dc.contributor.authorRua-Figueroa, I.
dc.contributor.authorGonzalez-Gay, M. A.
dc.contributor.authorGómez-Reino Carnota, Juan Jesús 
dc.contributor.authorAlvaro-Gracia, J. M.
dc.contributor.authorBiobadaser Study Group
dc.date.accessioned2022-05-05T08:29:03Z
dc.date.available2022-05-05T08:29:03Z
dc.date.issued2020
dc.identifier.issn0003-4967
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/32503857es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16693
dc.rightsAtribución-NoComercial 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subject.meshSpondylarthropathies*
dc.subject.meshRheumatic Diseases*
dc.subject.meshPandemics*
dc.subject.meshAdult*
dc.subject.meshMiddle Aged*
dc.subject.meshCoronavirus Infections*
dc.subject.meshGlucocorticoids*
dc.subject.meshPneumonia*
dc.subject.meshMethotrexate*
dc.subject.meshArthritis*
dc.subject.meshAntibodies*
dc.subject.meshHospitalization*
dc.subject.meshHumans*
dc.subject.meshAntirheumatic Agents*
dc.subject.meshInterleukin 1 Receptor Antagonist Protein*
dc.subject.meshHydroxychloroquine*
dc.subject.meshIntensive Care Units*
dc.subject.meshAged*
dc.titleClinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapiesen
dc.typeJournal Articlees
dc.authorsophosSanchez-Piedra, C.;Diaz-Torne, C.;Manero, J.;Pego-Reigosa, J. M.;Rua-Figueroa, I.;Gonzalez-Gay, M. A.;Gomez-Reino, J.;Alvaro-Gracia, J. M.;Grp, Biobadaser Study
dc.identifier.doi10.1136/annrheumdis-2020-217948
dc.identifier.pmid32503857
dc.identifier.sophos39959
dc.issue.number7es
dc.journal.titleAnnals of the rheumatic diseaseses
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Reumatoloxíaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Vigo - Complexo Hospitalario Universitario de Vigo::Reumatoloxíaes
dc.page.initial988es
dc.page.final990es
dc.rights.accessRightsopenAccess
dc.subject.decspandemias*
dc.subject.decsglucocorticoides*
dc.subject.decsmediana edad*
dc.subject.decsanticuerpos*
dc.subject.decsadulto*
dc.subject.decsantirreumáticos*
dc.subject.decsanciano*
dc.subject.decsneumonía*
dc.subject.decsmetotrexato*
dc.subject.decshospitalización*
dc.subject.decsenfermedades reumáticas*
dc.subject.decshumanos*
dc.subject.decsespondiloartropatías*
dc.subject.decsunidades de cuidados intensivos*
dc.subject.decshidroxicloroquina*
dc.subject.decsinfecciones por Coronavirus*
dc.subject.decsartritis*
dc.subject.decsproteína antagonista del receptor de interleucina 1*
dc.subject.keywordCHUSes
dc.subject.keywordCHUVIes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number79es


Files in this item

Download/Open
Name:
39959-1434.pdf
Size:
273.6Kb
Format:
PDF
Description:
Ann Rheum Dis . 2020 Jul;79(7):988-990

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución-NoComercial 4.0 Internacional